Wall Street Zen upgraded shares of Nephros (NASDAQ:NEPH – Free Report) to a strong-buy rating in a research note issued to investors on Saturday morning.
A number of other research analysts also recently commented on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Nephros in a research report on Wednesday, October 8th. Maxim Group raised their target price on shares of Nephros from $4.50 to $6.00 and gave the company a “buy” rating in a research report on Friday, August 8th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.50.
Read Our Latest Report on Nephros
Nephros Stock Performance
Nephros (NASDAQ:NEPH – Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.04. The business had revenue of $4.40 million for the quarter, compared to the consensus estimate of $3.60 million. Nephros had a net margin of 7.95% and a return on equity of 14.89%.
Institutional Trading of Nephros
An institutional investor recently raised its position in Nephros stock. Geode Capital Management LLC raised its holdings in shares of Nephros Inc. (NASDAQ:NEPH – Free Report) by 3.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 93,187 shares of the company’s stock after acquiring an additional 2,898 shares during the period. Geode Capital Management LLC owned approximately 0.88% of Nephros worth $381,000 at the end of the most recent quarter. Institutional investors own 41.10% of the company’s stock.
Nephros Company Profile
Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.
See Also
- Five stocks we like better than Nephros
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Johnson & Johnson’s M&A Strategy Is the Real Story for Investors
- Where Do I Find 52-Week Highs and Lows?
- Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?
- 3 Small Caps With Big Return Potential
- Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?
Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.